12833157	Peptides	Suzuki A	Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis.	Nature genetics	2003	209
27863183	Peptides	Pianta A	Evidence of the Immune Relevance of Prevotella copri, a Gut Microbe, in Patients With Rheumatoid Arthritis.	Arthritis & rheumatology	2017	11
26698023	Adenosine Triphosphate	Perl A	Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases.	Nature reviews. Rheumatology	2016	31
24696436	Anti-Bacterial Agents	Walker MJ	Disease manifestations and pathogenic mechanisms of Group A Streptococcus.	Clinical microbiology reviews	2014	91
27457513	Aspirin	Andreoli L	EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome.	Annals of the rheumatic diseases	2017	10
22293756	Cysteine	Harris HE	HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease.	Nature reviews. Rheumatology	2012	143
17469100	Methotrexate	Wolfe F	The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.	Arthritis and rheumatism	2007	59
17632266	Methotrexate	Ramos-Casals M	Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.	Medicine	2007	77
23687260	Methotrexate	Yoo DH	A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.	Annals of the rheumatic diseases	2013	70
24168956	Methotrexate	Smolen JS	Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial.	Lancet	2014	51
25367713	Methotrexate	Emery P	Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period.	Annals of the rheumatic diseases	2015	28
25660991	Methotrexate	Haschka J	Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study.	Annals of the rheumatic diseases	2016	12
25058083	Cyclophosphamide	van Laar JM	Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial.	JAMA	2014	46
28087505	Analgesics	van der Heijde D	2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.	Annals of the rheumatic diseases	2017	27
17599072	Uric Acid	Foell D	Mechanisms of disease: a 'DAMP' view of inflammatory arthritis.	Nature clinical practice. Rheumatology	2007	80
24226379	Anticoagulants	De Caterina R	Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease.	Thrombosis and haemostasis	2013	35
15505111	Adrenal Cortex Hormones	Newburger JW	Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.	Circulation	2004	282
15574639	Adrenal Cortex Hormones	Newburger JW	Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.	Pediatrics	2004	199
16730463	Adrenal Cortex Hormones	Roman-Blas JA	NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis.	Osteoarthritis and cartilage	2006	98
25887212	Adrenal Cortex Hormones	Maxwell LJ	TNF-alpha inhibitors for ankylosing spondylitis.	The Cochrane database of systematic reviews	2015	16
27307501	Adrenal Cortex Hormones	Cappelli LC	Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab.	Annals of the rheumatic diseases	2017	17
26644232	Anti-Inflammatory Agents, Non-Steroidal	Gossec L	European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.	Annals of the rheumatic diseases	2016	43
15207950	Antirheumatic Agents	McCarey DW	Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial.	Lancet	2004	122
16705046	Antirheumatic Agents	Hyrich KL	Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.	Rheumatology	2006	112
21843325	Antirheumatic Agents	Innala L	Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study.	Arthritis research & therapy	2011	44
25613167	Antirheumatic Agents	Kadavath S	Adult-onset Still's disease-pathogenesis, clinical manifestations, and new treatment options.	Annals of medicine	2015	16
25630559	Antirheumatic Agents	Murdaca G	Infection risk associated with anti-TNF-α agents: a review.	Expert opinion on drug safety	2015	16
25648633	Antirheumatic Agents	Kim GW	IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future.	Archives of pharmacal research	2015	18
19877063	collagen type I trimeric cross-linked peptide	Saag KG	Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.	Arthritis and rheumatism	2009	48
16447241	leflunomide	Wolfe F	Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy.	Arthritis and rheumatism	2006	64
26246395	Chloroquine	Rainsford KD	Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.	Inflammopharmacology	2015	23
27405509	Biological Products	Strangfeld A	Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs.	Annals of the rheumatic diseases	2017	6
24977961	Auranofin	Liu N	Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth.	Oncotarget	2014	34
25136784	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Calabrese LH	IL-6 biology: implications for clinical targeting in rheumatic disease.	Nature reviews. Rheumatology	2014	37
24387989	Amino Acids	Mayes MD	Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis.	American journal of human genetics	2014	40
25070946	Amino Acids	Okada Y	Risk for ACPA-positive rheumatoid arthritis is driven by shared HLA amino acid polymorphisms in Asian and European populations.	Human molecular genetics	2014	22
25651891	Amino Acids	Bowes J	Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis.	Nature communications	2015	29
25817017	Amino Acids	Carmona FD	A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility.	American journal of human genetics	2015	16
25919528	Amino Acids	Viatte S	Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response.	JAMA	2015	21
